Loading...
Please wait, while we are loading the content...
Similar Documents
A Phase II Trial of Deferoxamine in Patients with Hormone-Refractory Metastatic Prostate Cancer
| Content Provider | Scilit |
|---|---|
| Author | Dreicer, Robert Kemp, John D. Stegink, Lewis D. Cardillo, Thomas Davis, Charles S. Forest, Paula K. See, William A. |
| Copyright Year | 1997 |
| Description | The management of hormone-refractory metastatic prostate cancer remains a therapeutic dilemma. We report the results of a phase II trial with deferoxamine administered at a dose of 50 mg/kg (maximum dose 5 g) administered intravenously over 8 hr daily, repeated for 5 days at 4-week intervals for 2 courses. Fourteen patients with advanced hormone-refractory prostate cancer were treated and 28 courses were delivered. Essentially no toxicity was observed. Using combined clinical and prostate-specific antigen (PSA) criteria, 13 of 14 patients had disease progression. However, 9 of 14 patients had stable measurable or evaluable disease and progressed solely based on PSA criteria. Deferoxamine in this dose and schedule has no activity in hormone-refractory prostate cancer. Further investigation of the effect of deferoxamine on PSA production/expression is warranted. |
| Related Links | http://www.tandfonline.com/doi/pdf/10.3109/07357909709039731 |
| Ending Page | 317 |
| Page Count | 7 |
| Starting Page | 311 |
| ISSN | 07357907 |
| e-ISSN | 15324192 |
| DOI | 10.3109/07357909709039731 |
| Journal | Cancer Investigation |
| Issue Number | 4 |
| Volume Number | 15 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 1997-01-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Cancer Investigation Radiology, Nuclear Medicine and Imaging Prostate Cancer Metastatic Prostate Refractory Metastatic Hormone Refractory Deferoxamine Phase Ii Trial |
| Content Type | Text |
| Resource Type | Article |
| Subject | Cancer Research Oncology |
